U.S. In Vitro Diagnostics Market Share Analysis Report, 2023-2032
The U.S. in vitro diagnostics market size was exhibited at USD 58 billion in 2022 and is projected to hit around USD 93.58 billion by 2032, growing at a CAGR of 4.90% during the forecast period 2023 to 2032.
Key Pointers:
U.S. in Vitro Diagnostics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 60.84 billion |
| Market Size by 2032 | USD 93.58 billion |
| Growth Rate from 2023 to 2032 | CAGR of 4.90% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Technology, application, product, end-use |
| Key companies profiled | Abbott; bioMérieux; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Qiagen; Quidel Corporation; F. Hoffmann-La Roche Ltd.; BD (Becton Dickinson and Company); Thermo Fisher Scientific, Inc.; Ortho Clinical Diagnostics; Danaher Corporation. |
The market growth is declining due to a decrease in demand for COVID-19 tests during the forecast period. However, the development of automated in vitro diagnostic (IVD) systems for laboratories & hospitals to provide error-free, efficient, and accurate diagnosis is anticipated to drive the market over the study period. In addition, growing prevalence of infectious and chronic diseases is projected to boost adoption of in vitro diagnostic testing techniques in the U.S. For instance, according to the American Cancer Society, in 2023, about 1.96 million new cancer cases were reported and around 609,820 individuals died due to cancer.
Geriatric population in the U.S. is gradually increasing. According to America’s Health Rankings senior report, more than 54 million adults aged 65 & above are living in the U.S., accounting for 16.5% of the country’s population. By 2050, this number is estimated to surpass 85.7 million. Moreover, with rising age, immune system is affected, which surges susceptibility to numerous diseases. Thus, a large geriatric population needs improved healthcare, especially for diagnosis of chronic diseases. In addition, the geriatric population is more likely to suffer from COVID-19 due to decreased immune function, multimorbidity, and physiological changes associated with aging. According to the CDC data published in May 2023, the mortality rate due to COVID-19 is much higher in the geriatric population. The risk of death in COVID-19 patients aged 65 and above increases more than 60 times compared to the age group of 18 to 29.
Technological advancements in terms of accuracy, cost-effectiveness, and portability are anticipated to be among high-impact rendering drivers for in vitro diagnostics market. Leading market participants are updating their range of testing options for qPCR instruments by undertaking research and development (R&D) initiatives for development of kits that target life-threatening conditions or by entering into collaborations with other kit manufacturers. For instance, in March 2023, Atila Biosystems and Stilla Technologies agreed to market co-labeled digital PCR kits. The kits and assays are manufactured by Atila and would be used on naica systems, Stilla’s lead PCR instrument.In January 2023, QIAGEN launched EZ2 Connect MDx platform to propel its capabilities of automation in sample processing. The advancement would be compatible with PCR, dPCR, and other downstream applications.
Moreover, growing efforts from government and nongovernment organizations to promote development of rapid diagnostics solutions are anticipated to offer lucrative growth opportunities in U.S. market. For instance, in October 2022, a leader in infectious disease diagnostics, Day Zero Diagnostics, Inc., announced that it has been awarded additional funding of USD 8.2 million from CARB-X for development of precise and cutting-edge diagnostic solutions for infectious diseases. In addition, active government support to develop rapid diagnostics solutions is another factor contributing to the market growth. For instance, in October 2021, the NIH granted funding of USD 78 million to develop novel rapid diagnostics solutions for COVID-19. Ultimate aim of this funding was to develop PoC solutions for detecting multiple respiratory infections.
U.S. in Vitro Diagnostics Market Dynamics
Growing demand for personalized IVD instruments to achieve the best diagnostic standards is pressurizing the supply chain. Supply chain of diagnostic equipment and parts has received high attention following the turmoil in Chinese and Asian regions due to the pandemic. Increased freight prices and competition to acquire superior quality materials have intensified competitive rivalry among players. However, a rise in number of vaccinated individuals is projected to reduce the burden on IVD tests.
PCR capacity of the country has significantly escalated owing to increased installations of PCR machines during the pandemic. To utilize this newly acquired capacity, owners are trying to push alternative diagnostic tests to consumers. Regulatory framework for IVD has changed in the past year, and number of emergency approvals has increased to help companies address the pandemic. However, this may impact industry adversely once regulatory flexibility is removed in the post-pandemic era.
Stringent precision and calibration quality control mechanisms ensure the utmost quality of devices and analyzers. Outsourcing is also becoming a significant trend in the market, ensuring profitability and quality. For instance, the usual outsourcing destinations of U.S.-based companies are Asian nations such as China, Singapore, and India.
When compared to diagnostic equipment, the value chain is more complicated and highly impacted by fluctuations in the market due to its high demand. Hence, any changes in marketing environment may lead to a sudden surge or drop in demand, making inventory management difficult for companies. For instance, during the first wave of SARS-CoV-2 infection in the U.S., the sudden increase in demand for reagents led to shortage.
Key Companies & Market Share Insights
Major players are opting for market strategies for strategic collaborations and partnerships through mergers & acquisitions in the country.
Some of the prominent players in the U.S. in vitro diagnostics Market include:
Segments Covered in the Report
This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the U.S. in vitro diagnostics market.
By Product
By Technology
By Application
By End-use
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database:
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 U.S. IVD Market Variables, Trends, & Scope
3.1 IVD Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Driver Analysis
3.4.1 Growing Geriatric Population
3.4.2 Technological Advancements
3.4.3 Increasing Demand For Poc Facilities
3.4.4 Growing Prevalence Of Target Diseases Such As Genetic, Cardiovascular, And Neurological Diseases, And Hospital-Acquired Infections
3.4.5 Outbreak Of COVID-19
3.5 Market Restraint Analysis
3.5.1 Higher Cost Of Devices
3.5.2 Stringent Regulatory Policies
3.6 Value Chain Analysis
3.6.1 Value Chain Analysis/Route To Market
3.7 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.8 Porter’s Five Forces Analysis
3.9 Major Deals and Strategic Alliances Analysis
3.9.1 launch of New products
3.9.2 Mergers and acquisitions
3.9.3 Expansion
3.9.4 Partnerships
3.9.5 Marketing & promotions
3.10 Mergers And Deals
Chapter 4 U.S. IVD Market-Segment Analysis, by Product, 2023 - 2032
4.1 U.S. In Vitro Diagnostic Market: Products Movement Analysis
4.2 Instruments
4.2.1 Instruments Market Estimates And Forecast, 2020 - 2032 Volume (Number Of Instruments)
4.3 Reagents
4.3.1 Reagents Market Estimates And Forecast, 2020 - 2032 Volume (Number Of Tests)
4.4 Services
4.4.1 Services Market Estimates And Forecast, 2020 - 2032
Chapter 5 U.S. IVD Market-Segment Analysis, by Technology, 2023 - 2032
5.1 In Vitro Diagnostics Market: Technology Movement Analysis
5.2 Immunoassay
5.2.1 Immunoassay Market Estimates And Forecast, 2020 - 2032
5.2.2 Instruments
5.2.2.1 Instruments market for immunoassay estimates and forecast, 2020 - 2032 volume (number of instruments)
5.2.3 Reagents
5.2.3.1 Reagents market for immunoassay estimates and forecast, 2020 - 2032 volume (number of tests)
5.2.4 Services
5.2.4.1 Services market for immunoassay estimates and forecast, 2020 - 2032
5.3 Hematology
5.3.1 Hematology Market Estimates And Forecast, 2020 - 2032
5.3.2 Instruments
5.3.2.1 Instruments market for hematology estimates and forecast, 2020 - 2032 volume (number of instruments)
5.3.3 Reagents
5.3.3.1 Reagents market for hematology estimates and forecast, 2020 - 2032 volume (number of tests)
5.3.4 Services
5.3.4.1 Services market for hematology estimates and forecast, 2020 - 2032
5.4 Clinical Chemistry
5.4.1 Clinical Chemistry Market Estimates And Forecast, 2020 - 2032
5.4.2 Instruments
5.4.2.1 Instruments market for clinical chemistry estimates and forecast, 2020 - 2032 volume (number of instruments)
5.4.3 Reagents
5.4.3.1 Reagents market for clinical chemistry estimates and forecast, 2020 - 2032 volume (number of tests)
5.4.4 Services
5.4.4.1 Services market for clinical chemistry estimates and forecast, 2020 - 2032
5.5 Molecular Diagnostics
5.5.1 Moecular Diagnostics Market Estimates And Forecast, 2020 - 2032
5.5.2 Instruments
5.5.2.1 Instruments market for molecular diagnostics estimates and forecast, 2020 - 2032 volume (number of instruments)
5.5.3 Reagents
5.5.3.1 Reagents market for molecular diagnostics estimates and forecast, 2020 - 2032 volume (number of tests)
5.5.4 Services
5.5.4.1 Services market for molecular diagnostics estimates and forecast, 2020 - 2032
5.6 Coagulation
5.6.1 Coagulation Market Estimates And Forecast, 2020 - 2032
5.6.2 Instruments
5.6.2.1 Instruments market for coagulation estimates and forecast, 2020 - 2032 volume (number of instruments)
5.6.3 Reagents
5.6.3.1 Reagents market for coagulation estimates and forecast, 2020 - 2032 volume (number of tests)
5.6.4 Services
5.6.4.1 Services market for coagulation estimates and forecast, 2020 - 2032
5.7 Microbiology
5.7.1 Microbiology Market Estimates And Forecast, 2020 - 2032
5.7.2 Instruments
5.7.2.1 Instruments market for microbiology estimates and forecast, 2020 - 2032 volume (number of instruments)
5.7.3 Reagents
5.7.3.1 Reagents market for microbiology estimates and forecast, 2020 - 2032 volume (number of tests)
5.7.4 Services
5.7.4.1 Services market for microbiology estimates and forecast, 2020 - 2032
5.8 Others
5.8.1 Others Market Estimates And Forecast, 2020 - 2032
5.8.2 Instruments
5.8.2.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
5.8.3 Reagents
5.8.3.1 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
5.8.4 Services
5.8.4.1 Services market estimates and forecast, 2020 - 2032
Chapter 6 U.S. IVD Market: Segment Analysis, by End Use, 2023 - 2032
6.1 In Vitro Diagnostic Market: End-use Movement Analysis
6.2 Hospitals
6.2.1 Hospitals Market Estimates And Forecast, 2020 - 2032
6.2.2 Hospitals Market, By TechnologY
6.2.2.1 Immunoassay
6.2.2.2 Immunoassay market estimates and forecast, 2020 - 2032
6.2.2.2.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.2.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.2.3 Services market estimates and forecast, 2020 - 2032
6.2.2.3 Hematology
6.2.2.4 Hematology market estimates and forecast, 2020 - 2032
6.2.2.4.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.4.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.4.3 Services market estimates and forecast, 2020 - 2032
6.2.2.5 Clinical Chemistry
6.2.2.6 Clinical chemistry market estimates and forecast, 2020 - 2032
6.2.2.6.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.6.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.6.3 Services market estimates and forecast, 2020 - 2032
6.2.2.7 Molecular Diagnostics
6.2.2.8 Molecular diagnostics market estimates and forecast, 2020 - 2032
6.2.2.8.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.8.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.8.3 Services market estimates and forecast, 2020 - 2032
6.2.2.9 Coagulation
6.2.2.10 Coagulation market estimates and forecast, 2020 - 2032
6.2.2.10.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.10.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.10.3 Services market estimates and forecast, 2020 - 2032
6.2.2.11 Microbiology
6.2.2.12 Microbiology market estimates and forecast, 2020 - 2032
6.2.2.12.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.12.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.12.3 Services market estimates and forecast, 2020 - 2032
6.2.2.13 Others
6.2.2.14 Others market estimates and forecast, 2020 - 2032
6.2.2.14.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.2.2.14.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.2.2.14.3 Services market estimates and forecast, 2020 - 2032
6.3 Laboratory
6.3.1 Laboratory Market Estimates And Forecast, 2020 - 2032
6.3.2 Laboratory Market, By Technology
6.3.2.1 Immunoassay
6.3.2.2 Immunoassay market estimates and forecast, 2020 - 2032
6.3.2.2.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.2.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.2.3 Services market estimates and forecast, 2020 - 2032
6.3.2.3 Hematology
6.3.2.4 Hematology market estimates and forecast, 2020 - 2032
6.3.2.4.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.4.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.4.3 Services market estimates and forecast, 2020 - 2032
6.3.2.5 Clinical Chemistry
6.3.2.6 Clinical chemistry market estimates and forecast, 2020 - 2032
6.3.2.6.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.6.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.6.3 Services market estimates and forecast, 2020 - 2032
6.3.2.7 Molecular Diagnostics
6.3.2.8 Molecular diagnostics market estimates and forecast, 2020 - 2032
6.3.2.8.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.8.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.8.3 Services market estimates and forecast, 2020 - 2032
6.3.2.9 Coagulation
6.3.2.10 Coagulation market estimates and forecast, 2020 - 2032
6.3.2.10.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.10.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.10.3 Services market estimates and forecast, 2020 - 2032
6.3.2.11 Microbiology
6.3.2.12 Microbiology market estimates and forecast, 2020 - 2032
6.3.2.12.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.12.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.12.3 Services market estimates and forecast, 2020 - 2032
6.3.2.13 Others
6.3.2.14 Others market estimates and forecast, 2020 - 2032
6.3.2.14.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.3.2.14.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.3.2.14.3 Services market estimates and forecast, 2020 - 2032
6.4 Home Care
6.4.1 Home Care Market Estimates And Forecast, 2020 - 2032
6.4.2 Home Care Market, By Technology
6.4.2.1 Immunoassay
6.4.2.2 Immunoassay market estimates and forecast, 2020 - 2032
6.4.2.2.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.2.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.2.3 Services market estimates and forecast, 2020 - 2032
6.4.2.3 Hematology
6.4.2.4 Hematology market estimates and forecast, 2020 - 2032
6.4.2.4.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.4.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.4.3 Services market estimates and forecast, 2020 - 2032
6.4.2.5 Clinical Chemistry
6.4.2.6 Clinical chemistry market estimates and forecast, 2020 - 2032
6.4.2.6.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.6.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.6.3 Services market estimates and forecast, 2020 - 2032
6.4.2.7 Molecular Diagnostics
6.4.2.8 Molecular diagnostics market estimates and forecast, 2020 - 2032
6.4.2.8.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.8.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.8.3 Services market estimates and forecast, 2020 - 2032
6.4.2.9 Coagulation
6.4.2.10 Coagulation market estimates and forecast, 2020 - 2032
6.4.2.10.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.10.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.10.3 Services market estimates and forecast, 2020 - 2032
6.4.2.11 Microbiology
6.4.2.12 Microbiology market estimates and forecast, 2020 - 2032
6.4.2.12.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.12.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.12.3 Services market estimates and forecast, 2020 - 2032
6.4.2.13 Others
6.4.2.14 Others market estimates and forecast, 2020 - 2032
6.4.2.14.1 Instruments market estimates and forecast, 2020 - 2032 volume (number of instruments)
6.4.2.14.2 Reagents market estimates and forecast, 2020 - 2032 volume (number of tests)
6.4.2.14.3 Services market estimates and forecast, 2020 - 2032
6.5 Others
6.5.1 Other Market Estimates And Forecast, 2020 - 2032
Chapter 7 U.S. IVD Market: Segment Analysis, by Application, 2020 - 2032
7.1 U.S. In Vitro Diagnostics Market: Application Movement Analysis
7.2 Infectious Diseases
7.2.1 Infectious Diseases Market Estimates And Forecast, 2020 - 2032
7.2.1.1 Upper respiratory
7.2.1.1.1 Upper respiratory market estimates and forecast, 2020 - 2032
7.2.1.2 Gastrointestinal panel testing
7.2.1.2.1 Gastrointestinal panel testing market estimates and forecast, 2020 - 2032
7.2.1.3 Methicillin-resistant Staphylococcus Aureus (MRSA)
7.2.1.3.1 MRSA market estimates and forecast, 2020 - 2032
7.2.1.4 Clostridium difficile
7.2.1.4.1 Clostridium difficile market estimates and forecast, 2020 - 2032
7.2.1.5 Vancomycin-Resistant Enterococci (VRE)
7.2.1.5.1 VRE market estimates and forecast, 2020 - 2032
7.2.1.6 Carbapenem-resistant bacteria
7.2.1.6.1 Carbapenem-resistant bacteria market estimates and forecast, 2020 - 2032
7.2.1.7 Flu
7.2.1.7.1 Flu market estimates and forecast, 2020 - 2032
7.2.1.8 Respiratory Syncytial Virus (RSV)
7.2.1.8.1 RSV market estimates and forecast, 2020 - 2032
7.2.1.9 Candida
7.2.1.9.1 Candida market estimates and forecast, 2020 - 2032
7.2.1.10 Tuberculosis (TB) and drug-resistant TB
7.2.1.10.1 TB and drug-resistant TB market estimates and forecast, 2020 - 2032
7.2.1.11 Meningitis
7.2.1.11.1 Meningitis market estimates and forecast, 2020 - 2032
7.2.1.12 Chlamydia
7.2.1.12.1 Chlamydia market estimates and forecast, 2020 - 2032
7.2.1.13 Gonorrhoea
7.2.1.13.1 Gonorrhoea market estimates and forecast, 2020 - 2032
7.2.1.14 HIV
7.2.1.14.1 HIV market estimates and forecast, 2020 - 2032
7.2.1.15 Hepatitis C
7.2.1.15.1 Hepatitis C market estimates and forecast, 2020 - 2032
7.2.1.16 Hepatitis B
7.2.1.16.1 Hepatitis B market estimates and forecast, 2020 - 2032
7.2.1.17 Other infectious disease market
7.2.1.17.1 Other infectious disease market estimates and forecast, 2020 - 2032
7.3 Diabetes
7.3.1 Diabetes Market Estimates And Forecast, 2020 - 2032
7.4 Oncology
7.4.1 Oncology Market Estimates And Forecast, 2020 - 2032
7.5 Cardiology
7.5.1 Cardiology Market Estimates And Forecast, 2020 - 2032
7.6 Nephrology
7.6.1 Nephrology Market Estimates And Forecast, 2020 - 2032
7.7 Autoimmune Diseases
7.7.1 Autoimmune Diseases Market Estimates And Forecast, 2020 - 2032
7.8 Drug Testing
7.8.1 Drug Testing Market Estimates And Forecast, 2020 - 2032
7.9 Hematologic Diseases
7.9.1 Hematologic Diseases Market Estimates And Forecast, 2020 - 2032
7.10 Others
7.10.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 8 U.S. IVD Market: Segment Analysis, by Region, 2020 - 2032
8.1 Regional Analysis - The U.S. IVD Market
8.1.1 Trends In U.S. IVD Market
8.1.2 U.S. IVD Market Estimates And Forecast, 2020 - 2032
Chapter 9 Competitive Analysis
9.1 Recent Developments and Impact Analysis, by Key Market Participants
9.1.1 ANSOFF MATRIX
9.1.2 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
9.1.3 Innovators
9.2 Vendor Landscape
9.2.1 List Of Key Distributors And Channel Partners
9.2.2 U.S. IVD Market: Key Company Market Share Analysis, 2022
9.2.3 Competitive Dashboard Analysis
9.2.4 Strategic Framework
9.3 Private Companies
9.3.1 List Of Key Emerging Companies /Technology Disruptors/Innovators
9.3.2 Regional Network Map
9.4 Company Profiles
9.4.1 ABBOTT
9.4.1.1 Company overview
9.4.1.2 Alere, Inc.
9.4.1.3 Financial performance
9.4.1.4 Product benchmarking
9.4.1.5 Strategic initiatives
9.4.2 BIOMÉRIEUX SA
9.4.2.1 Company overview
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 BIO-RAD LABORATORIES, INC.
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 BECTON, DICKINSON AND COMPANY
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product benchmarking
9.4.4.4 Strategic initiatives
9.4.5 SIEMENS HEALTHINEERS AG
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product benchmarking
9.4.5.4 Strategic initiatives
9.4.6 QIAGEN
9.4.6.1 Company overview
9.4.6.2 Financial performance
9.4.6.3 Product benchmarking
9.4.6.4 Strategic initiatives
9.4.7 QUIDEL CORPORATION
9.4.7.1 Company Overview
9.4.7.2 Financial Performance
9.4.7.3 Product benchmarking
9.4.7.4 Strategic initiatives
9.4.8 F. HOFFMANN-LA ROCHE LTD.
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
9.4.9 SYSMEX CORPORATION
9.4.9.1 Company overview
9.4.9.2 Financial performance
9.4.9.3 Product benchmarking
9.4.9.4 Strategic initiatives
9.4.10 QUEST DIAGNOSTICS
9.4.10.1 Company overview
9.4.10.2 Financial Performance
9.4.10.3 Product benchmarking
9.4.10.4 Strategic initiatives
9.4.11 AGILENT TECHNOLOGIES, INC.
9.4.11.1 Company overview
9.4.11.2 Financial performance
9.4.11.3 Product benchmarking
9.4.11.4 Strategic initiatives
9.4.12 DANAHER CORPORATION
9.4.12.1 Company overview
9.4.12.2 Cepheid
9.4.12.3 Beckman Coulter
9.4.12.4 Leica Biosystems
9.4.12.5 Financial performance
9.4.12.6 Product benchmarking
9.4.12.7 Strategic initiatives
9.4.12.8 Strategic initiatives - Beckman Coulter, Inc.
9.4.12.9 Strategic initiatives - Leica Biosystems
Chapter 10 U.S. IVD Market: Competitive Landscape By Application, H. Pylori Market
10.1 Company Profiles
10.1.1 MERIDIAN BIOSCIENCE, INC.
10.1.1.1 Company overview
10.1.1.2 Financial performance
10.1.1.3 Product benchmarking
10.1.1.4 Strategic initiatives
10.1.2 ABBOTT
10.1.2.1 Company overview
10.1.2.2 Alere, Inc.
10.1.2.3 Financial performance
10.1.2.4 Product benchmarking
10.1.3 THERMO FISHER SCIENTIFIC INC.
10.1.3.1 Company overview
10.1.3.2 Financial performance
10.1.3.3 Product benchmarking
10.1.4 EPITOPE DIAGNOSTICS, INC
10.1.4.1 Product benchmarking
10.1.5 BIO-RAD LABORATORIES, INC.
10.1.5.1 Company overview
10.1.5.2 Financial performance
10.1.5.3 Product benchmarking
10.1.6 SEKISUI DIAGNOSTICS, LLC
10.1.6.1 Company overview
10.1.6.2 Financial performance
10.1.6.3 Product benchmarking
10.1.7 DIASORIN MOLECULAR LLC
10.1.7.1 Company overview
10.1.7.2 Financial performance
10.1.7.3 Product benchmarking
10.1.7.4 Strategic initiatives
10.1.8 QUEST DIAGNOSTICS
10.1.8.1 Company overview
10.1.8.2 Financial Performance
10.1.8.3 Product benchmarking
10.1.9 BIOHIT OYJ
10.1.9.1 Financial performance
10.1.9.2 Product benchmarking
10.1.10 QUIDEL CORPORATION
10.1.10.1 Company Overview
10.1.10.2 Financial Performance
10.1.10.3 Product benchmarking
10.2 Public Companies Analysis
10.2.1 Company Market Position Analysis
10.2.2 Competitive Dashboard Analysis
10.2.2.1 Market Differentiators
10.3 Private Companies Analysis
10.4 Key company market share analysis, 2022
Chapter 11 U.S. IVD Market: Competitive Landscape By Application, C. difficile Market
11.1 Company Profiles
11.1.1 MERIDIAN BIOSCIENCE, INC.
11.1.1.1 Company overview
11.1.1.2 Financial performance
11.1.1.3 Product benchmarking
11.1.2 ALTONA DIAGNOSTICS GMBH
11.1.2.1 Company overview
11.1.2.2 Product benchmarking
11.1.3 THERMO FISHER SCIENTIFIC, INC.
11.1.3.1 Company overview
11.1.3.2 Financial performance
11.1.3.3 Product benchmarking
11.1.4 TRINITY BIOTECH PLC
11.1.4.1 Financial performance
11.1.4.2 Product benchmarking
11.1.5 ABNOVA CORPORATION
11.1.5.1 Financial performance
11.1.5.2 Product benchmarking
11.1.6 BD (BECTON, DICKINSON AND COMPANY)
11.1.6.1 Company overview
11.1.6.2 Company overview
11.1.6.3 Financial performance
11.1.6.4 Product benchmarking
11.1.7 TECHLAB INC.
11.1.7.1 Product benchmarking
11.1.8 F. HOFFMANN-LA ROCHE LTD
11.1.8.1 Company overview
11.1.8.2 Financial performance
11.1.8.3 Product benchmarking
11.1.9 ANTYLIA SCIENTIFIC
11.1.9.1 ZeptoMetrix
11.1.9.2 Product benchmarking
11.1.10 QUIDEL CORPORATION
11.1.10.1 Company Overview
11.1.10.2 Financial Performance
11.1.10.3 Product benchmarking
11.1.10.4 Strategic initiatives
11.2 Public Companies Analysis
11.2.1 Company Market Position Analysis
11.2.2 Competitive Dashboard Analysis
11.2.2.1 Market Differentiators
11.3 Private Companies Analysis
11.4 Key company market share analysis, 2022
Chapter 12 U.S. IVD Market: Competitive Landscape By Application, Shiga Toxin (E. coli) Market
12.1 Company Profiles and Recent Developments & Impact Analysis, By Key Market Participants
12.1.1 MERIDIAN BIOSCIENCE, INC.
12.1.1.1 Company overview
12.1.1.2 Financial performance
12.1.1.3 Product benchmarking
12.1.2 ABBOTT
12.1.2.1 Company overview
12.1.2.2 Alere, Inc.
12.1.2.3 Financial performance
12.1.2.4 Product benchmarking
12.1.3 THERMO FISHER SCIENTIFIC, INC.
12.1.3.1 Company overview
12.1.3.2 Financial performance
12.1.3.3 Product benchmarking
12.1.3.4 Strategic initiatives
12.1.4 BIOMÉRIEUX SA
12.1.4.1 Company overview
12.1.4.2 Financial performance
12.1.4.3 Product benchmarking
12.1.5 BIO-RAD LABORATORIES, INC.
12.1.5.1 Company overview
12.1.5.2 Financial performance
12.1.5.3 Product benchmarking
12.1.5.4 Strategic initiatives
12.1.6 ALTONA DIAGNOSTICS GMBH
12.1.6.1 Company overview
12.1.6.2 Product benchmarking
12.1.7 DIASORIN MOLECULAR LLC
12.1.7.1 Company overview
12.1.7.2 Financial performance
12.1.7.3 Product benchmarking
12.1.8 F. HOFFMANN-LA ROCHE LTD.
12.1.8.1 Company overview
12.1.8.2 Financial performance
12.1.8.3 Product benchmarking
12.1.9 QIAGEN
12.1.9.1 Company overview
12.1.9.2 Financial performance
12.1.9.3 Product benchmarking
12.1.10 QUIDEL CORPORATION
12.1.10.1 Company Overview
12.1.10.2 Financial Performance
12.1.10.3 Product benchmarking
12.2 Public Companies Analysis
12.2.1 Company Market Position Analysis
12.2.2 Competitive Dashboard Analysis
12.2.2.1 Market Differentiators
12.3 Private Companies Analysis
12.4 Key company market share analysis, 2022
Chapter 13 U.S. IVD Market: Competitive Landscape By Application, Strep A and Strep B Market
13.1 Company Profiles
13.1.1 MERIDIAN BIOSCIENCE, INC.
13.1.1.1 Company overview
13.1.1.2 Financial performance
13.1.1.3 Product benchmarking
13.1.2 ABBOTT
13.1.2.1 Company overview
13.1.2.2 Alere, Inc.
13.1.2.3 Financial performance
13.1.2.4 Product benchmarking
13.1.2.5 Strategic initiatives
13.1.3 THERMO FISHER SCIENTIFIC INC.
13.1.3.1 Company overview
13.1.3.2 Financial performance
13.1.3.3 Product benchmarking
13.1.3.4 Strategic initiatives
13.1.4 BIOMÉRIEUX SA
13.1.4.1 Company overview
13.1.4.2 Financial performance
13.1.4.3 Product benchmarking
13.1.5 BIO-RAD LABORATORIES, INC.
13.1.5.1 Company overview
13.1.5.2 Financial performance
13.1.5.3 Product benchmarking
13.1.6 SSI DIAGNOSTICA
13.1.6.1 Company overview
13.1.6.2 CTK biotech INC.
13.1.6.3 Product benchmarking
13.1.7 DIASORIN MOLECULAR LLC
13.1.7.1 Company overview
13.1.7.2 Financial performance
13.1.7.3 Product benchmarking
13.1.7.4 Strategic initiatives
13.1.8 F. HOFFMANN-LA ROCHE LTD.
13.1.8.1 Company overview
13.1.8.2 Financial performance
13.1.8.3 Product benchmarking
13.1.9 QIAGEN
13.1.9.1 Company overview
13.1.9.2 Financial performance
13.1.9.3 Product benchmarking
13.1.10 QUIDEL CORPORATION
13.1.10.1 Company Overview
13.1.10.2 Financial Performance
13.1.10.3 Product benchmarking
13.1.10.4 Strategic initiatives
13.2 Public Companies Analysis
13.2.1 Company Market Position Analysis
13.2.2 Competitive Dashboard Analysis
13.2.2.1 Market Differentiators
13.3 Private Companies Analysis
13.4 Key company market share analysis, 2022
Chapter 14 U.S. IVD Market: Competitive Landscape By Application, Blood/hematology lead detection Market
14.1 Company Profiles
14.1.1 MERIDIAN BIOSCIENCE, INC.
14.1.1.1 Magellan Diagnostics
14.1.1.2 Financial performance
14.1.1.3 Product benchmarking
14.1.1.4 Strategic initiatives
14.1.2 MERCK KGAA
14.1.2.1 Financial performance
14.1.2.2 Product benchmarking
14.1.3 BD (Becton, Dickinson And Company)
14.1.3.1 Company overview
14.1.3.2 Financial performance
14.1.3.3 Product benchmarking
14.2 List of Lead Testing Laboratory
14.3 Public Companies Analysis
14.3.1 Company Market Position Analysis
14.3.2 Competitive Dashboard Analysis
14.3.2.1 Market Differentiators
14.4 Private Companies Analysis
Chapter 15 U.S. IVD Market: Competitive Landscape By Application, Influenza Market
15.1 Company Profiles
15.1.1 ABBOTT
15.1.1.1 Company overview
15.1.1.2 Alere, Inc.
15.1.1.3 Financial performance
15.1.1.4 Product benchmarking
15.1.1.5 Strategic initiatives
15.1.2 BD (BECTON, DICKINSON AND COMPANY)
15.1.2.1 Company overview
15.1.2.2 Financial performance
15.1.2.3 Product benchmarking
15.1.2.4 Strategic initiatives
15.1.3 QUIDEL CORPORATION
15.1.3.1 Company Overview
15.1.3.2 Financial Performance
15.1.3.3 Product Benchmarking
15.1.3.4 Strategic Initiatives
15.1.4 THERMO FISHER SCIENTIFIC, INC.
15.1.4.1 Company overview
15.1.4.2 Financial performance
15.1.4.3 Product benchmarking
15.1.4.4 Strategic initiatives
15.1.5 LUMINEX CORPORATION
15.1.5.1 Company overview
15.1.5.2 Financial performance
15.1.5.3 Product benchmarking
15.1.5.4 Strategic initiatives
15.1.6 CEPHEID (DANAHER CORPORATION)
15.1.6.1 Company Overview
15.1.6.2 Financial Performance
15.1.6.3 Product Benchmarking
15.1.6.4 Strategic Initiatives
15.1.7 MERIDIAN BIOSCIENCE, INC.
15.1.7.1 Company overview
15.1.7.2 Financial performance
15.1.7.3 Product benchmarking
15.1.7.4 Strategic initiatives
15.1.8 BIOMÉRIEUX SA
15.1.8.1 Company overview
15.1.8.2 Financial performance
15.1.8.3 Product benchmarking
15.1.8.4 Strategic initiatives
15.1.9 SEKISUI DIAGNOSTICS
15.1.9.1 Company overview
15.1.9.2 Financial performance
15.1.9.3 Product benchmarking
15.1.9.4 Strategic initiatives
15.1.10 SIEMENS HEALTHINEERS
15.1.10.1 Company overview
15.1.10.2 Financial performance
15.1.10.3 Product benchmarking
15.2 Recent Developments and Impact Analysis, by Key Market Participants
15.2.1 Major Deals And Strategic Alliances Analysis
15.2.1.1 New Product Launches
15.2.1.2 Mergers and Acquisitions
15.2.1.3 Partnerships and Strategic Collaboration
15.2.1.4 Conferences and Campaigns
15.3 Public Companies Analysis
15.3.1 Company Market Position Analysis
15.3.2 Competitive Dashboard Analysis
15.3.2.1 Market Differentiators
15.4 Private Companies Analysis
15.5 Key company market share analysis, 2022
Chapter 16 U.S. IVD Market: Competitive Landscape By Application, STDs Market
16.1 Company Profiles
16.1.1 ABBOTT
16.1.1.1 Company overview
16.1.1.2 Alere, Inc.
16.1.1.3 Financial performance
16.1.1.4 Product benchmarking
16.1.1.5 Strategic initiatives
16.1.2 BD (BECTON, DICKINSON AND COMPANY)
16.1.2.1 Company overview
16.1.2.2 Financial performance
16.1.2.3 Product benchmarking
16.1.2.4 Strategic initiatives
16.1.3 SIEMENS HEALTHINEERS
16.1.3.1 Company overview
16.1.3.2 Financial performance
16.1.3.3 Product benchmarking
16.1.3.4 Strategic initiatives
16.1.4 BIOMÉRIEUX SA
16.1.4.1 Company overview
16.1.4.2 Financial performance
16.1.4.3 Product benchmarking
16.1.5 BIO-RAD LABORATORIES, INC.
16.1.5.1 Company overview
16.1.5.2 Financial performance
16.1.5.3 Product benchmarking
16.1.5.4 Strategic initiatives
16.1.6 DANAHER CORPORATION
16.1.6.1 Company overview
16.1.6.2 Cepheid
16.1.6.3 Beckman Coulter
16.1.6.4 Leica Biosystems
16.1.6.5 Financial performance
16.1.6.6 Product benchmarking
16.1.7 DIASORIN MOLECULAR LLC
16.1.7.1 Company overview
16.1.7.2 Financial performance
16.1.7.3 Product benchmarking
16.1.7.4 Strategic initiatives
16.1.8 HOLOGIC, INC.
16.1.8.1 Company overview
16.1.8.2 Financial performance
16.1.8.3 Product benchmarking
16.1.8.4 Strategic initiatives
16.1.9 F. HOFFMANN-LA ROCHE LTD
16.1.9.1 Company overview
16.1.9.2 Financial performance
16.1.9.3 Product benchmarking
16.1.9.4 Strategic initiatives
16.1.10 QIAGEN
16.1.10.1 Company overview
16.1.10.2 Financial performance
16.1.10.3 Product benchmarking
16.1.10.4 Strategic initiatives
16.2 Recent Developments and Impact Analysis, by Key Market Participants
16.2.1 Major Deals And Strategic Alliances Analysis
16.2.1.1 New product launches
16.2.1.2 Mergers and acquisitions
16.2.1.3 Expansion
16.2.1.4 Partnerships and collaborations
16.3 Public Companies Analysis
16.3.1 Company Market Position Analysis
16.3.2 Competitive Dashboard Analysis
16.3.2.1 Market Differentiators
16.4 Private Companies Analysis
16.5 Key company market share analysis, 2022
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers